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Methods 
The CT scans prior to radiation treatment from 30 patients were 
pulled from EPIC. Cross-sectional imaging was manually 
segmented first using Velocity software , and then auto-
segmented with an AI model. Both software were used to extract 
lean body mass (LBM), subcutaneous fat, and intra-abdominal 
fat body mass alterations from baseline, and stratified using the 
skeletal muscle index (SMI) in the third lumbar level to  assess 




We hypothesize that if we train a deep learning 
system based on manual segmentation, we will 
be able to extract quantitative data for the lean 
body mass and adiposity pre and post radiation 
treatment. Figure 1B. Manually segmented  cross-sectional imaging of  L3 .Blue 
shows subcutaneous fat, green shows  lean body mass and pink 
shows segmented intracutaneous fat body mass. 
Results 
Manual segmentation was collected on 30 
patients and auto-segmentation of LBM, 
subcutaneous fat, and intracutaneous fat 
body mass is underway. Statistical analysis 
will assess the association between delta-
LBM, subcutaneous fat, and intracutaneous 
fat body mass from pre-treatment and 
MDASI-HN overall score, multi-variable 
effects of chemotherapy variables, and 
sarcopenia, and construction of toxicity 
prediction nomograms.
Discussion
After conducting the segmentation part of 
the project, we aim to predict post-
radiotherapy sarcopenia and define what 
effects, if any, systemic agent selection 
might have upon resultant late toxicity. 
This will improve patient’s care because 
it will allow physicians to be able to 
change treatments if needed to prevent 
cancer induced sarcopenia based on the 
prediction. It would also allow physicians 
to administer appetite stimulants as a 
preventive measure.
Background
Sarcopenia is the decrease of lean body mass usually due 
to either loss of muscle cells or as a result of 
cachexia. Most cancer patients experience this life-
altering side effects post chemoradiotherapy, some of 
which includes loss of lean body mass, cancer therapy-
induced nutritional compromise, and systemic effect of 
chemoradiotherapy. Previous experiments in our lab have 
shown that the onset of sarcopenia during 
chemoradiotherapy was associated with reduced survival 
and cancer control in head and neck cancer patients. 
However, these data were from HPV + patients who 
received feeding tubes which showed a correlation 
between toxicity, sarcopenia, and oncologic outcome. The 
aim of our project is to predict the development of post-
therapy sarcopenia and define what effects, if any, 
systemic agent selection might have upon resultant late 
toxicity. 
Figure 1A. Unsegmented cross-sectional imaging of  L3.
